Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-59067
Leo, C; Fink, D (2011). Erythropoietin in der onkologischen Therapie – was wissen wir über die Risiken? Praxis, 100(20):1239-46.
PDF - Registered users only
View at publisher
Erythropoietin is a glycoprotein predominantly produced in the kidney. It is an essential regulator of erythropoiesis in the bone marrow. Although cancer-associated anemia is caused by multiple factors, recombinant erythropoietin (rhuEpo) was widely used to treat and prevent this condition. Several clinical studies showed that the use of rhuEpo results in an efficient reduction of red blood cell transfusions in cancer-associated anemia. However, over the past twenty years, Epo and its receptor EpoR were found to be expressed also outside the hematopoietic system and in malignant tumors. This led to a discussion concerning potential risks associated with the application of erythropoiesis-stimulating agents in oncology.
2 downloads since deposited on 17 Feb 2012
0 downloads since 12 months
|Other titles:||Erythropoietinin oncologic therapy - what so we know about the risks?|
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology|
|DDC:||610 Medicine & health|
|Deposited On:||17 Feb 2012 12:24|
|Last Modified:||09 Oct 2013 11:11|
|ISSN:||1661-8157 (P) 1661-8165 (E)|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page